Blood filter trial offers new hope for chronic fatigue sufferers
NCT ID NCT07529197
First seen Apr 25, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This study looks at whether a blood-filtering treatment called immunoadsorption (IA) can improve symptoms in people with ME/CFS (chronic fatigue syndrome) or post-COVID ME/CFS who have certain autoantibodies. Researchers will track 50 patients over time to see if removing these antibodies helps with physical function, energy, and daily activities. The goal is to find a better treatment for a condition that currently has no cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ME/CFS FOLLOWING COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité - Universitätsmedizin Berlin
RECRUITINGBerlin, State of Berlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.